Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PORTAPHAR: Ceftriaxone Sparing for Asymptomatic Pharyngeal Gonorrhea
NCT05971550Phase 3Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Reversible Covalent Inhibitors
01
Overview
A Phase 3 trial of ceftriaxone in gonorrhea, sponsored by Assistance publique - Hôpitaux de Paris. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
ceftriaxone
03
Conditions
gonorrhea
Beyond the preview
Go deeper on NCT05971550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05971550.